Suswapna Singh Rawat: The Role of Platelets in Heart Disease and Antiplatelet Therapy
Suswapna Singh Rawat,Physician shared a post on LinkedIn:
“Platelets play a crucial role in managing ruptures within blood vessels and contributing to blockages in smaller vessels.
While they are essential for clotting, in cases of established heart disease, stents, or bypasses, reducing their activity becomes vital.
Antiplatelet medications like aspirin, clopidogrel, dipyridamole, and ticagrelor are instrumental in these scenarios.
They work by making blood less prone to clotting and aggregation, thereby easing passage through blockages.
For individuals without existing heart conditions, platelets have a less pronounced role, but for those with diagnosed heart disease or recent interventions, these medications are critical.
Management of heart disease is multifactorial, involving measures to reduce blood pressure, inflammation, and LDL cholesterol, alongside controlling platelet activity.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 9, 2026, 06:39Chaza Alaji: How Hemophilia Became a Disease of Precision Medicine
-
Sep 9, 2026, 05:52Faheema Hasan: New ASH 2026 Guidelines Redefine Initial and Second-Line ITP Therapy
-
Sep 9, 2026, 05:43Thomas Pincez: Clonal Hematopoiesis Linked to Increased Risk of Autoimmune Hemolytic Anemia
-
Sep 9, 2026, 05:33Marianne Yee: Sickle Cell Disease and the Human Side of Medical Research
-
Sep 8, 2026, 16:14Heghine Khachatryan: Colombo 2026 Insights on Point-of-Care Ultrasound in Hemophilia Joint Care
-
Sep 8, 2026, 15:57Flora Peyvandi: Efficiency Meets Innovation in Hemophilia B Gene Therapy
-
Sep 8, 2026, 15:48Maxime Dely: Guillain-Barré Syndrome – What if the Key Lies in the Plasma?
-
Sep 8, 2026, 15:34Ron DePinho: A Negative Trial Highlights the Need for Precision in Cardiovascular Inflammation
-
Sep 8, 2026, 15:31Adil Yousaf: Thrombolysis Speed Matters, but Eligibility Comes First